News / Taiwan / cnyes
JieLiKang to Debut on Emerging Stock Market on Aug 31, Targeting Soft Tissue Repair Market
Health Technology · Biotechnology · cnyes · 2026-08-24
7686
Biotech firm JieLiKang (7686) is set to list on the emerging stock market on August 31, leveraging its proprietary LipoShell and HeliBarb platforms to capture growth in breast reconstruction and medical aesthetics.
What Happened
Market Debut: JieLiKang (7686) has announced its official listing on the emerging stock market scheduled for August 31, with a current paid-in capital of NT$501 million. Chairman Tseng Yu-chia stated that the company is leveraging its core technological platforms to address growing demands in breast reconstruction and medical aesthetics.
Core Technology Platforms: The company utilizes its LipoShell platform for soft tissue reconstruction, employing biodegradable materials to facilitate tissue regeneration. Having completed large animal trials, the company aims to initiate human clinical trials by the first quarter of 2028, while the HeliBarb platform focuses on providing stable support through a patented non-barbed spiral design.
Aesthetics Product Pipeline: The first product under the HeliBarb platform, the JOUVENCE bio-absorbable lifting thread, is currently undergoing regulatory review in Taiwan. The product is designed to provide uniform and stable lifting support, marking a key milestone in the company's product development strategy.
International Expansion: Chairman Tseng noted that JOUVENCE is primarily targeting the Japanese market, with a potential launch expected as early as next year. Beyond Japan, the company is actively planning to expand its footprint into Southeast Asian markets, including Thailand and the Philippines, to drive future growth.